Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.58 |
| ▸ | GAA | P10253 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | LGMN | Q99538 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | RAD52 | P43351 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29949140 | 1.00 | MAPT (0.58) | MAPTGAASMN1; SMN2LGMNALDH1A1 | |
| SCHEMBL7039460 | 0.86 | MAPT (0.51) | MAPTGAASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL24630249 | 0.84 | MAPT (0.61) | MAPTGAASMN1; SMN2LGMNALDH1A1 | |
| SCHEMBL29769230 | 0.84 | MAPT (0.61) | MAPTGAASMN1; SMN2LGMNALDH1A1 | |
| SCHEMBL17536983 | 0.84 | SMN1; SMN2 (0.50) | MAPTGAASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL16454989 | 0.82 | MAPT (0.58) | MAPTGAASMN1; SMN2LGMNALDH1A1 | |
| SCHEMBL29889006 | 0.82 | CCR5 (0.47) | MAPTGAASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL27159794 | 0.82 | CCR5 (0.47) | MAPTGAASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL13455200 | 0.81 | MAPT (0.61) | MAPTGAASMN1; SMN2LGMNALDH1A1 | |
| SCHEMBL188672 | 0.81 | MAPT (0.61) | MAPTGAASMN1; SMN2LGMNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466841-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12071442-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240190895-A1 | SUBSTITUTED PYRROLO[3,4-c]PYRIDINES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2024-06-13 | — | — | US | disclosed |
| CN-117377673-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20220363695-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. | 2022-11-17 | — | — | US | disclosed |
| US-9850247-B2 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | ALMAC HOUSE (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3083625-B1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-11-01 | — | — | EP | disclosed |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3083625-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | Almac Discovery Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092431-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363695-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | MAPT 3895/4885GAA 905/4885SMN1; SMN2 3277/4885 |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | MAPT 3728/4885GAA 1730/4885SMN1; SMN2 4422/4885 |
| US-12466841-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | PDXK, HIPK1, HIPK3 | MAPT 3393/4885GAA 2502/4885SMN1; SMN2 3266/4885 |
| US-12071442-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | PDXK, HIPK1, PGK1 | MAPT 3822/4885GAA 2572/4885SMN1; SMN2 3520/4885 |
| US-20240190895-A1 | SUBSTITUTED PYRROLO[3,4-c]PYRIDINES AS HPK1 ANTAGONISTS | PDXK, HIPK1, HIPK3 | MAPT 3393/4885GAA 2502/4885SMN1; SMN2 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.